According to Express Scripts 2013 Drug Spending Trends report, spending on hepatitis C drugs will soar 102% this year and more than 200% next year, as doctors increasingly prescribe next-generation treatments from Gilead (NASDAQ:GILD) and Johnson & Johnson (NYSE:JNJ).
Those two treatments, both of which won FDA approval late last year, posted significant sales during the first quarter. However, another new wave of promising hepatitis C treatments are awaiting FDA approval, suggesting there may be significant shifts in market share by the end of the year.
In the following slideshow, you'll learn how much Gilead and Johnson generated in revenue from their new drugs during the first quarter, and why AbbVie (NYSE:ABBV) and Bristol-Myers (NYSE:BMY) may win away market share later this year.
Six stock picks poised for incredible growth
They said it couldn't be done. But David Gardner has proved them wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently, one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.
Todd Campbell is long Gilead. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd owns Gundalow Advisors, LLC. Gundalow's clients do not have positions in the companies mentioned. The Motley Fool recommends Gilead Sciences and Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.